MIMEDX GROUP, INC. (MDXG) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$4.44

From 52W high−44.97%

Volume2.69M

Market cap$639.19M

P/E (TTM)109.5x

P/S (TTM)1.8x

Div yield—

Key dataOct 19, 2026

Open

$4.44

From 52W high

−44.97%

Volume

2.69M

Market cap

$639.19M

ValuationView details →

P/E (Fwd)

31.0x

EV/EBITDA

21.3x

P/E (TTM)

109.5x

RSI (14)

35.3

MomentumView details →

1D Return

−1.13%

YTD Return

−36.12%

SummaryUpdated Jun 1, 2026

MiMedx Group, Inc. (NASDAQ:MDXG) is a biotechnology company founded in 2008 and headquartered in Marietta, Georgia. The company specializes in developing and distributing placental tissue allografts for various healthcare applications. MiMedx has established itself as a leader in the regenerative medicine space, processing human placental tissues through its proprietary PURION process to create biological products that retain the tissue's natural healing properties. The company has evolved from its early focus on wound care into a diversified portfolio serving surgical recovery, burn treatment, and other medical applications.

Ask drillr about MIMEDX GROUP, INC. →

ValuationView details →

P/E (Fwd)

31.0x

P/E (TTM)

109.5x

EV/EBITDA

21.3x

EV/Sales

1.4x

P/S (TTM)

1.8x

P/B (TTM)

3.0x

ProfitabilityView details →

Gross Margin

78.85%

Net Margin

1.76%

EBITDA Margin

6.67%

ROE (TTM)

2.89%

ROA (TTM)

2.22%

Asset Turnover

1.20x

GrowthView details →

Revenue YoY

−2.36%

EPS YoY

−81.88%

FCF YoY

−22.04%

Revenue CAGR 3Y

+16.05%

EPS CAGR 3Y

−17.08%

EBITDA YoY

−57.48%

MomentumView details →

1D Return

−1.13%

YTD Return

−36.12%

1Y Return

−35.93%

RSI (14)

35.3

vs 50D SMA

−4.96%

vs 200D SMA

−1.10%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

5.33x

Quick Ratio

4.79x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.05

EPS Surprise

−1.01%

Beats (12Q)

7/12

Next Q EPS Est

$0.03

Avg Surprise (4Q)

38.63%

Rev Surprise

−2.09%

Financials snapshotView financials →

Revenue (TTM)

355.17M

Net Income (TTM)

6.24M

Op. CF (TTM)

46.15M

Next earningsOct 28, 2026 →

Latest newsMore news →

Sanara MedTech Inc. and MIMEDX GROUP, INC.'s deal spread widened after the Federal Trade Commission issued a second request in connection with their deal.3d ago

MiMedx Group announced that it will report third-quarter 2026 operating and financial results after the market close on October 28, 2026, followed by a management webcast and conference call at 4:30 p.m. Eastern Time.5d ago

Similar companies

Brii Biosciences Limited02137.HK Solid Biosciences Inc.SLDB Attovia Therapeutics, Inc.ATTO Pharming Group N.V.PHAR Gyre Therapeutics, Inc.GYRE Sagimet Biosciences Inc.SGMT Find similar companies →

Latest newsMore news →

Sanara MedTech Inc. and MIMEDX GROUP, INC.'s deal spread widened after the Federal Trade Commission issued a second request in connection with their deal.3d ago MiMedx Group announced that it will report third-quarter 2026 operating and financial results after the market close on October 28, 2026, followed by a management webcast and conference call at 4:30 p.m. Eastern Time.5d ago